Medical School
Baylor College of Medicine (1996)
Baylor College of Medicine (1999), Internal Medicine
UT Southwestern Medical Center (2002), Infectious Diseases
Other Post Graduate Training
University of Texas Health Science Center at Dallas (2004)
Graduate School
University of Texas Health Science Center at Dallas (2004), Public Health

Research Interest

  • Hepatitis B
  • Hepatitis C
  • HIV and complications
  • HIV and Liver Disease
  • Influenza
  • Viral Eradication


Featured Publications LegendFeatured Publications

Half of 30-Day Hospital Readmissions Among HIV-Infected Patients Are Potentially Preventable.
Nijhawan AE, Kitchell E, Etherton SS, Duarte P, Halm EA, Jain MK AIDS Patient Care STDS 2015 Jul
Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Baker J, Engen N, Huppler Hullsiek K, Stephan C, Jain M, Munderi P, Pett S, Duprez D HIV Med. 2015 Apr 16 Suppl 1 109-18
Faldaprevir and pegylated interferon a-2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV.
Dieterich D, Nelson M, Soriano V, Arastéh K, Guardiola JM, Rockstroh JK, Bhagani S, Laguno M, Tural C, Ingiliz P, Jain MK, Stern JO, Manero M, Vinisko R, Kort J AIDS 2015 Mar 29 5 571-81
Micro-RNA-122 levels in acute liver failure and chronic hepatitis C.
Dubin PH, Yuan H, Devine RK, Hynan LS, Jain MK, Lee WM J. Med. Virol. 2014 Jun
Acute and chronic immune biomarker changes during interferon/ribavirin treatment in HIV/HCV co-infected patients.
Jain MK, Adams-Huet B, Terekhova D, Kushner LE, Bedimo R, Li X, Holodniy M J. Viral Hepat. 2014 Feb
The RADAR Study: Week 48 Safety and Efficacy of RAltegravir Combined with Boosted DARunavir Compared to Tenofovir/Emtricitabine Combined with Boosted Darunavir in Antiretroviral-Naive Patients. Impact on Bone Health.
Bedimo RJ, Drechsler H, Jain M, Cutrell J, Zhang S, Li X, Farukhi I, Castanon R, Tebas P, Maalouf NM PLoS ONE 2014 9 8 e106221
Knowledge and attitudes about hepatitis C virus (HCV) infection and its treatment in HCV mono-infected and HCV/HIV co-infected adults.
Chen EY, North CS, Fatunde O, Bernstein I, Salari S, Day B, Jain MK J. Viral Hepat. 2013 Oct 20 10 708-14
Patient perspectives on hepatitis C and its treatment.
North CS, Devereaux R, Pollio DE, Hong BA, Jain MK Eur J Gastroenterol Hepatol 2013 Jun
Pegylated interferon fractal pharmacokinetics: individualized dosing for hepatitis C virus infection.
Jain MK, Pasipanodya JG, Alder L, Lee WM, Gumbo T Antimicrob. Agents Chemother. 2013 Mar 57 3 1115-20
Suppression of HBV by tenofovir in HBV/HIV coinfected patients: a systematic review and meta-analysis.
Price H, Dunn D, Pillay D, Bani-Sadr F, de Vries-Sluijs T, Jain MK, Kuzushita N, Mauss S, Núñez M, Nüesch R, Peters M, Reiberger T, Stephan C, Tan L, Gilson R PLoS ONE 2013 8 7 e68152

Honors & Awards

  • Fellow of Infectious Disease Society of America
  • Best Doctors in Dallas "D Magazine"
  • K23 NIH Grant
  • Student Research Grant
  • Training Award
    Patient Oriented Research (2001)
  • Travel Grant Award
    Outstanding Abstract Submission, IDSA (2001)

Professional Associations/Affiliations

  • Texas Infectious Disease Society (2018)
  • Infectious Disease Society of America, Fellow (2015)
  • American Association for the Study of Liver Disease (2003)
  • Infectious Disease Society of America (2002)